AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04406493 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung impedance technique
Description: COVID 19 patients are admitted to the Infectious Diseases Unit; they will undergo examination using a lung impedance device. The first value that has been measured will be set as BASAL.~During the hospitalization, each patient will undergo this examination twice a day until discharge.~Changes in impedance values during admission will be evaluated as POSITIVE AND NEGATIVE PREDICTIVE values for clinical deterioration and improvement of COVID 19 patients and as a factor which predicts mechanical ventilation.~The time between lung impedance started to decrease (expression of the lung fluids accumulation), and the need for mechanical ventilation will be measured.
Study NCT03298646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: 10 ml of 2% lidocaine on hysteroscopic infusion media during office hysteroscopy.
Study NCT03298646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: 100 mg Diclofenac oral tablet one hour before the procedure.
Study NCT00698646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan + HCTZ
Description: At week 0 patients received V+HCTZ 160+12.5 mg capsules. Subjects not at BP goal \<140/90 mmHg were uptitrated to V+HCTZ 320+12.5 mg at week 4 and if needed to V+HCTZ 320+25 mg at week 8 or 12.
Study NCT00698646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: At week 0 patients received Valsartan(V) 160 mg capsule. Subjects not at BP goal \<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.
Study NCT00698646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCTZ
Description: At week 0 patients received HCTZ 12.5 mg capsule. Subjects not at BP goal \<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.
Study NCT01400503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: Type=exact number, unit=mg/kg, number=11, form=intravenous solution, route=intravenous. Siltuximab given as a 1-hour infusion every 3 weeks.
Study NCT02058615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Male Spouse Transition Toolkit
Study NCT04674124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Online Mindfulness Intervention
Description: A nine-week mindfulness course compromising of 9x weekly 15 minute group sessions which will be on an online platform and daily micro meditations for participants to undertake.
Study NCT00609427 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MEMO programme (Inst Universitaire de Geriatrie, Montreal)
Description: 8 weekly group training sessions in mnemonic strategies, administered by clinical psychologist.
Study NCT00609427 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: External memory aids training
Description: 8 weekly group sessions of training in the use of external memory aids, administered by clinical psychologist
Study NCT03131557 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Line extension of the Phonak Audéo B product family
Description: The line extension of the Phonak Audéo B product family will be fitted to the participants individual hearing loss.
Study NCT03131557 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phonak Audéo B
Description: Phonak Audéo B will be fitted to the participants individual hearing loss.
Study NCT02170740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS - low dose
Study NCT02170740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS - high dose
Study NCT02170740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS + Pantoprazole
Study NCT03341793 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Muscle biopsy and blood test
Description: Characterize the changes in muscle secretion induced by bariatric surgery and determine their role in improving the insulin sensitivity of skeletal muscle and insulin secretion by B cell responsible for the remission of diabetes mellitus.
Study NCT02721082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opt Out Treatment Program
Description: Tobacco Treatment (UKanQuit) staff will complete a treatment plan for all participants.
Study NCT02721082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: Unless they Opt Out all participants will be provided with a 14 day supply of the nicotine patch and nicotine mini-lozenges or nicotine gum, depending on study related criteria.
Study NCT02721082 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Opt In Treatment Program
Description: Tobacco Treatment (UKanQuit) staff will complete a treatment plan for participant's who are ready to quit smoking. For patient's not ready to quit, motivational counseling will be provided to participants based on principles of Motivational Interviewing.
Study NCT02721082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy
Description: Participants ready to quit will be provided with a 14 day supply of the nicotine patch and nicotine mini-lozenges or nicotine gum, depending on study related criteria.
Study NCT01001052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colcrys™ (colchicine)
Description: 0.6 mg taken by mouth on day 1
Study NCT00860379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selenium1
Description: 2 ug/kg
Study NCT00860379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selenium2
Description: 4 ug/kg
Study NCT00860379 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV saline as placebo
Study NCT01458197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarafenacin 0.2 mg
Description: Capsule, qd, 12 weeks
Study NCT01458197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, qd, 12 weeks
Study NCT01458197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarafenacin 0.4 mg
Description: Capsule, qd, 12 weeks
Study NCT02415101 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resective surgery
Study NCT03152383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training trials
Description: A highly preferred edible item will be selected to teach the contingencies for the assessment. Materials to engage in the work response (i.e., button press) will be placed within arm's reach of the child, and the edible item will be in sight. The therapist will deliver a vocal prompt for the child to engage in the work response (e.g., press the button and you can have some candy). If the child engages in the response, the therapist immediately delivers the edible item. The therapist will guide the child to engage in the instrumental response, and will then gradually begin to fade the prompt level. If the child makes an error at any level of prompting, the therapist will guide the participant to emit a correct response. The edible item will be delivered to the child each time that the child responds correctly at any prompt level.
Study NCT03152383 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training trials
Description: A highly preferred edible item will be selected to teach the contingencies for the assessment. Materials to engage in the work response (i.e., button press) will be placed within arm's reach of the child, and the edible item will be in sight. The therapist will deliver a vocal prompt for the child to engage in the work response (e.g., press the button and you can have some candy). If the child engages in the response, the therapist immediately delivers the edible item. The therapist will guide the child to engage in the instrumental response, and will then gradually begin to fade the prompt level. If the child makes an error at any level of prompting, the therapist will guide the participant to emit a correct response. The edible item will be delivered to the child each time that the child responds correctly at any prompt level.
Study NCT03152383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Ratio Session
Description: The child will be guided to engage in the instrumental response then the stimulus will be immediately delivered for 30 seconds. The leisure item or the individual who will provide attention will be directly outside of the session room. If the child emits the work response, they will be allowed access to either a leisure item or to attention (depending on the condition) for 30 seconds. The child is initially required to respond one time, then they will be required to respond two times to gain access to the item or attention (then 4, then 8, and so on) such that the response requirement progressively increases according to a pre-determined schedule. A minimum of 3 sessions will be conducted for each condition. The amount of time required for participation depends on the child's responding, and caregiver availability. Participation may take as little as a couple hours, or as long as 3-4 hours per day for approximately one week.
Study NCT03152383 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Ratio Session
Description: The child will be guided to engage in the instrumental response then the stimulus will be immediately delivered for 30 seconds. The leisure item or the individual who will provide attention will be directly outside of the session room. If the child emits the work response, they will be allowed access to either a leisure item or to attention (depending on the condition) for 30 seconds. The child is initially required to respond one time, then they will be required to respond two times to gain access to the item or attention (then 4, then 8, and so on) such that the response requirement progressively increases according to a pre-determined schedule. A minimum of 3 sessions will be conducted for each condition. The amount of time required for participation depends on the child's responding, and caregiver availability. Participation may take as little as a couple hours, or as long as 3-4 hours per day for approximately one week.
Study NCT03152383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Re-test
Description: 10 children with ASD will return to repeat the progressive ratio (PR) assessment one week after completing it the first time to examine the reliability of the measure.
Study NCT03152383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pairing Protocol
Description: 15 children with ASD will receive an intervention designed to increase social approach after completing the PR assessment. Participants will attend 2 hour appointments 3-5 days per week in which a therapist will deliver highly preferred items, play with the child, work on teaching communication skills, and teach the child to comply with demands. After completing the intervention (once the child is willingly staying near and interacting with the therapist and complying with instructions), the PR assessment will be repeated to measure change due to the intervention.
Study NCT02400138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory training
Description: Respiratory training will include training of the inspiratory and expiratory muscle seven times per week over eight weeks, during 40 minutes, divided into two 20-min sessions (morning and afternoon). Each 20-min session comprised 4-min sets of respiratory training, followed by 1-min rest between the sets. The training program will be carried-out with the Orygen Dual Valve regulated at 50% of the subjects' maximal inspiratory and expiratory pressure values. Once a week, the treating physiotherapist performed a home visit, measured the current values of inspiratory and expiratory strength, and progressed the load to 50% of the new values.
Study NCT02400138 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: The control/sham group will underwent exactly the same protocol and weekly monitoring at home, but the participants will receive the devices without resistance of the spring.
Study NCT03876405 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smartskin non-invasive sensory feedback
Description: The sensory feedback system used was a simple non-invasive, non-electronic system based on air-mediated pressure. A silicone glove with bulbs (35 mm in length) volar in every fingertip was made and applied on a VariPlus Speed hand (OttoBock), size 7¾.~The sensory feedback system was embedded in the prosthetic socket.
Study NCT04944641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education on epilepsy
Description: education on epilepsy, including epilepsy diary, pamphlet，discussion between patients and phone visits and so on
Study NCT04944641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: routine and proper antiepileptic drugs
Description: routine and proper antiepileptic drugs
Study NCT01474733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: series of lectures and workshops on health literacy
Study NCT01015157 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y laparoscopic gastric bypass for morbid obesity
Description: Primary bariatric surgery. Standard laparoscopic procedure with linear stapling divising of the stomach (Echelon 60 stapler, GOLD cartridges) with or with Seamguard reinforcement
Study NCT01536132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan
Description: 0.2 micrograms/kg/min is administered intravenously without bolus for 6 hours every two weeks.
Study NCT01536132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (same appearance than active drug) is administered with the same dosing regime
Study NCT01298999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YF476
Description: 25 mg: one capsule to be taken by mouth once daily for 12 weeks.
Study NCT01298999 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo: one capsule to be taken by mouth once daily for 12 weeks.
Study NCT01543061 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OPTIVEtm Plus
Description: 1 drop in each eye four times a day for a period of 30 (± 3) days
Study NCT01543061 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: No treatment
Description: One month of contact lens wear with no eye drop use
Study NCT01543061 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blink Contacts® Eye Drops
Description: 1 drop in each eye four times a day for a period of 30 (± 3) days
Study NCT04359472 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Application of Autologous Amniotic Fluid
Description: Collection and reapplication of amniotic fluid at wound layers during a cesarean section.
Study NCT00100685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volociximab (anti-α5β1 integrin monoclonal antibody)
Description: Volociximab intravenously (Cohort 1: 10 mg/kg every other week or Cohort 2: 15 mg/kg once a week) for up to 104 weeks or until disease progression, whichever occurs first.
Study NCT04560491 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Intraoperative examination of sentinel node
Description: Intraoperative examination of sentinel node by either frozen section or scrape cytology to detect metastasis and decide for further lymphadenectomy.
Study NCT01190696 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: titanium elastic nailing
Description: we inserted titanium nail in femoral fractures retrogradely
Study NCT01190696 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hip spica casting
Description: we applied cast for three weeks in patients with femoral shaft fracture
Study NCT00981084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: armodafinil
Description: Half of the patients will be randomized to receive a single oral dose of placebo prior to the first testing session. After a washout period of one week, they will then receive 250mg of armodafinil prior to a second testing session (P/A group). The other half of patients will be randomized to receive the active drug first. After a washout period of one week, they will receive the placebo prior to a second testing session (A/P group). As plasma levels of armodafinil peak between 2-4 hours after administration, participants will be asked to take a single 250mg capsule 2 hours prior to the scheduled testing sessions.
Study NCT01944865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval Training
Description: The interval training group consisted of 7 to 10 repetitions of 4-6 min at the highest intensity sustainable, the active recovery was 4-6 min in intensity from 10 to 15 of scale of perceived exertion CR100.
Study NCT01944865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Training
Description: The riders of intermittent training group completed 8 to 12 repetitions of 30 s all-out with 4 min of active recovery.
Study NCT02479230 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine
Description: Given ID
Study NCT02479230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT01735890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ Amlodipine/Valsartan 10/160mg Novartis Exforge 10/160mg
Description: single dose
Study NCT01735890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CJ Amlodipine/Valsartan 10/160mg Novartis Exforge 10/160mg
Description: single dose
Study NCT04062357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 5% spray
Description: Group 1 (n₌75); was given on demand lidocaine 5% spray for 8 weeks (One to two applications (1-2 ml) of lidocaine 5% sprays; contain 5 -10 mg of lidocaine, in a metered dose aerosol-delivery system).
Study NCT04062357 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group 2 (n₌75); was given placebo in form on demand alcohol spray for 8 weeks.
Study NCT00842140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral contraceptive
Description: oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate)once a day for 12 months
Study NCT00842140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral contraceptive plus spironolactone
Description: The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 100 mg spironolactone. One pill each once a day for twelve months.
Study NCT00842140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral contraceptive plus metformin
Description: Oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 850 mg of metformin
Study NCT04197713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Given PO
Study NCT04197713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT03512652 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Patello
Description: The Patello is a new intervention device which mobilizes the Patella passively and continuously in cranial-caudal direction to increase Patella mobility.
Study NCT04168554 — intervention group
Intervention type: DEVICE
Intervention: Telemedicine
Description: Patient is examined using telemedicine
Study NCT04718428 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nail Ultrasonography
Description: The MyLab 60 (Esaote Biomedica Genoa, Italy) device and linear probe were used. Nails were examined in B-mode grayscale and power Doppler.
Study NCT01394393 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experiential-Cognitive Therapy for Obesity
Description: Is a relatively short-term, integrated, patient oriented approach that focuses on individual discovery (Riva, Bacchetta, Baruffi, Rinaldi, \& Molinari, 1998, 1999; Riva et al., 2000). It shares with the cognitive-behavioral approach proposed by Cooper and colleagues the use of a combination of cognitive and behavioral procedures to help the patient identify and change the maintaining mechanisms (Cooper et al., 2003). However, it considers morbid obesity as a peculiar form of addiction. So, as in the cognitive-behavioral treatment of addictions (Carroll et al., 1994) the two main goals are the functional analysis of the maintaining mechanisms and the required skill training (relapse prevention).
Study NCT01394393 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral cognitive Treatment
Description: Therapists will follow a detailed manual that outlined the content of each session. This manual was based on the cognitive-behavioral treatment approach described by Cooper and colleagues (Cooper \& Fairburn, 2002; Cooper et al., 2003). It was developed during a year of intensive pilot work and adapted to the in-patient setting. Patients will be taught to self-monitor their food intake and eating patterns and thoughts, as well as the circumstances and environment surrounding eating (e.g. whether eating alone or with others, speed of eating, and place of eating). Patients will also be taught to identify problems in eating, mood, and thinking patterns and to gradually develop alternative patterns.
Study NCT01394393 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Nutritional groups (NT)
Description: 5 weekly nutritional treatment based on the LEARN manual (Brownell, 1985), whose goal will be to provide practical guidelines for the self-monitoring of eating and lessons on nutrition (e.g stressing gradual weight loss with the caloric restriction achieved largely by reductions in fat intake), plus a low-calorie diet (1,200 kcal/day) and physical training (30 min of walking two times a week as a minimum).